CoronaryAtlas logo
CoronaryAtlas
Lipoprotein-associated Phospholipase A2
Pathway / Plaque inflammation

Lipoprotein-associated Phospholipase A2

PLA2G7protein

Lp-PLA2 generates inflammatory mediators from oxidized lipids within atherosclerotic plaques, promoting destabilization and rupture.

Pathway placement
Cascade stepPlaque inflammation
Confidencehigh
RationaleLp-PLA2 hydrolyzes oxidized phospholipids in oxLDL; drives plaque inflammation and rupture risk.
Also acts inLipid entry/oxidation, Platelet activation
Druggability
DruggableYes
Known drugs / candidates2
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000146070

Type I vs Type II discrimination

ScoresIndeterminate
R — rupture / Type-I
—
C — confounder / Type-II
33
A — assay feasibility
72
E — evidence strength
48
T1DI (composite)
14
Specificity differential (R−C)-18.3
Confounder panel (Type-II drivers)
1sepsis / systemic inflammationn/a
2anemia / acute blood lossn/a
3hypovolemia / dehydrationn/a
4tachyarrhythmiamag 1
5hypoxemia / respiratory failuren/a
6hypertensive emergencyn/a
7high-demand / peri-operative stressn/a
Coverage: 1/7 confounders with evidence
Tier: deep-scored (abstract-extracted) · 2 supporting references. See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)

Human genetic evidence

0.001
Open Targets association (NSTEMI)

Literature evidence(24)

Clinical trials(4)